REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.58 Billion KRW | -51.8% |
| 2022 | 7.43 Billion KRW | 34.25% |
| 2021 | 5.53 Billion KRW | 44.03% |
| 2020 | 3.84 Billion KRW | -35.3% |
| 2019 | 5.94 Billion KRW | 342.45% |
| 2018 | 1.34 Billion KRW | -89.58% |
| 2017 | 12.88 Billion KRW | 20.42% |
| 2016 | 10.7 Billion KRW | -5.61% |
| 2015 | 11.33 Billion KRW | -2.2% |
| 2014 | 11.59 Billion KRW | 2.66% |
| 2013 | 11.29 Billion KRW | -33.53% |
| 2012 | 16.99 Billion KRW | -14.1% |
| 2011 | 19.77 Billion KRW | -1.01% |
| 2010 | 19.98 Billion KRW | 22.68% |
| 2009 | 16.28 Billion KRW | 101.95% |
| 2008 | 8.06 Billion KRW | 32.52% |
| 2007 | 6.08 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 326.16 Million KRW | 132.97% |
| 2024 Q2 | 659.64 Million KRW | 102.24% |
| 2023 Q4 | -989.35 Million KRW | -880.31% |
| 2023 Q2 | 2.66 Billion KRW | 32.82% |
| 2023 Q3 | -100.92 Million KRW | -103.79% |
| 2023 FY | 3.58 Billion KRW | -51.8% |
| 2023 Q1 | 2 Billion KRW | -48.06% |
| 2022 Q4 | 3.86 Billion KRW | 85.1% |
| 2022 Q3 | 2.08 Billion KRW | 605.14% |
| 2022 Q1 | 1.89 Billion KRW | 29.26% |
| 2022 FY | 7.43 Billion KRW | 34.25% |
| 2022 Q2 | -413.33 Million KRW | -121.82% |
| 2021 Q3 | 14.46 Million KRW | -99.53% |
| 2021 Q1 | 1.01 Billion KRW | -35.93% |
| 2021 FY | 5.53 Billion KRW | 44.03% |
| 2021 Q2 | 3.04 Billion KRW | 201.52% |
| 2021 Q4 | 1.46 Billion KRW | 10032.62% |
| 2020 Q3 | 882.42 Million KRW | -35.68% |
| 2020 Q2 | 1.37 Billion KRW | 11531.38% |
| 2020 Q1 | 11.79 Million KRW | -97.37% |
| 2020 FY | 3.84 Billion KRW | -35.3% |
| 2020 Q4 | 1.57 Billion KRW | 78.71% |
| 2019 Q2 | 1.37 Billion KRW | -50.86% |
| 2019 Q4 | 449.17 Million KRW | -66.17% |
| 2019 FY | 5.94 Billion KRW | 342.45% |
| 2019 Q1 | 2.79 Billion KRW | 169.57% |
| 2019 Q3 | 1.32 Billion KRW | -3.25% |
| 2018 Q3 | 443.56 Million KRW | -89.12% |
| 2018 FY | 1.34 Billion KRW | -89.58% |
| 2018 Q4 | -4.01 Billion KRW | -1004.98% |
| 2018 Q2 | 4.07 Billion KRW | 396.25% |
| 2018 Q1 | 821.45 Million KRW | -33.2% |
| 2017 FY | 12.88 Billion KRW | 20.42% |
| 2017 Q4 | 1.22 Billion KRW | -59.88% |
| 2017 Q3 | 3.06 Billion KRW | -11.53% |
| 2017 Q2 | 3.46 Billion KRW | -25.5% |
| 2017 Q1 | 4.65 Billion KRW | 135.84% |
| 2016 Q3 | 2.28 Billion KRW | -1.53% |
| 2016 FY | 10.7 Billion KRW | -5.61% |
| 2016 Q4 | 1.97 Billion KRW | -13.65% |
| 2016 Q2 | 2.31 Billion KRW | -43.77% |
| 2016 Q1 | 4.12 Billion KRW | 941.61% |
| 2015 Q3 | 3.8 Billion KRW | 16.95% |
| 2015 Q4 | 396.07 Million KRW | -89.59% |
| 2015 Q2 | 3.25 Billion KRW | -16.22% |
| 2015 Q1 | 3.88 Billion KRW | 44.26% |
| 2015 FY | 11.33 Billion KRW | -2.2% |
| 2014 Q4 | 2.69 Billion KRW | -17.02% |
| 2014 Q2 | 2.7 Billion KRW | -8.59% |
| 2014 Q1 | 2.95 Billion KRW | -15.8% |
| 2014 FY | 11.59 Billion KRW | 2.66% |
| 2014 Q3 | 3.24 Billion KRW | 20.06% |
| 2013 Q1 | 2.42 Billion KRW | -47.28% |
| 2013 Q2 | 1.62 Billion KRW | -32.95% |
| 2013 Q4 | 3.51 Billion KRW | -6.02% |
| 2013 Q3 | 3.73 Billion KRW | 129.93% |
| 2013 FY | 11.29 Billion KRW | -33.53% |
| 2012 FY | 16.99 Billion KRW | -14.1% |
| 2012 Q4 | 4.59 Billion KRW | -3.52% |
| 2012 Q3 | 4.76 Billion KRW | 5.92% |
| 2012 Q2 | 4.49 Billion KRW | 43.61% |
| 2012 Q1 | 3.13 Billion KRW | -32.54% |
| 2011 Q2 | 4.46 Billion KRW | -32.73% |
| 2011 Q1 | 6.63 Billion KRW | 26.44% |
| 2011 Q3 | 4.03 Billion KRW | -9.64% |
| 2011 Q4 | 4.64 Billion KRW | 15.07% |
| 2011 FY | 19.77 Billion KRW | -1.01% |
| 2010 Q3 | 5.86 Billion KRW | 29.23% |
| 2010 FY | 19.98 Billion KRW | 22.68% |
| 2010 Q2 | 4.53 Billion KRW | 0.0% |
| 2010 Q4 | 5.24 Billion KRW | -10.44% |
| 2009 FY | 16.28 Billion KRW | 101.95% |
| 2008 FY | 8.06 Billion KRW | 32.52% |
| 2007 FY | 6.08 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 149.901% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 93.821% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 106.014% |
| HANDOK Inc. | -28.79 Billion KRW | 112.443% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 142.582% |
| Yuhan Corporation | 93.5 Billion KRW | 96.168% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 67.783% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 114.442% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 97.55% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -2.131% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 242.968% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 272.783% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 179.193% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 83.955% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 149.901% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 117.112% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 103.03% |
| JW Holdings Corporation | 19.02 Billion KRW | 81.166% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 104.54% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 98.314% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 90.317% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 106.251% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 41.465% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -115.407% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 28.4% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 149.901% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 90.306% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 96.786% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 90.317% |
| Yuhan Corporation | 93.5 Billion KRW | 96.168% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 122.052% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 192.461% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 41.441% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 90.317% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 81.046% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 92.575% |
| CKD Bio Corp. | -24.19 Billion KRW | 114.812% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 85.017% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 86.94% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 87.965% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 106.251% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 92.377% |
| Boryung Corporation | 40.2 Billion KRW | 91.087% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 111.438% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 242.968% |
| JW Lifescience Corporation | 28.14 Billion KRW | 87.268% |